RBC finds Abbott Q1 readthrough positive for Dexcom, Edwards

Medtronic

17/04/2026 13:09

** RBC Capital Markets sees support for steady procedure-demand backdrop for the MedTech sector in Abbott's ABT.N Q1 medical device growth

** Says ABT Q1 performance is supportive for cardiovascular-exposed names and broader MedTech procedure volumes

** Finds readthrough positive for Dexcom DXCM.O, Edwards Lifesciences EW.N; neutral for Boston Scientific BSX.N, Medtronic MDT.N

** Abbott on Thursday flagged company-specific headwinds but forecast a return to double-digit growth in Q2

** Firm had a limited Q1 impact on BSX, MDT but expects this to accelerate with broader rollout of new electrophysiology products - RBC

** Adds that expectations already reflect this outlook, particularly for BSX, which has guided to ~15% 2026 growth, including ~10% U.S. growth

** BSX, EW report next week, followed by DXCM on April 30; MDT update due early June

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))